S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$41.25
-0.22 (-0.53%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$41.02
$41.51
50-Day Range
$38.05
$43.53
52-Week Range
$33.53
$43.61
Volume
4.09 million shs
Average Volume
3.78 million shs
Market Capitalization
$111.07 billion
P/E Ratio
17.48
Dividend Yield
4.98%
Beta
0.74
30 days | 90 days | 365 days | Advanced Chart
Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GlaxoSmithKline and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline logo

About GlaxoSmithKline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
94,066
Year Founded
2000

Sales & Book Value

Annual Sales
$43.79 billion
Cash Flow
$3.85 per share
Book Value
$11.14 per share

Profitability

Net Income
$7.38 billion
Pretax Margin
16.93%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,692,590,000
Free Float
2,423,336,000
Market Cap
$111.07 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/27/2021
Ex-Dividend
11/18/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Dividend Payable
1/13/2022
Next Earnings (Estimated)
2/02/2022

Social Links


MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1066th out of 1,390 stocks

Pharmaceutical Preparations Industry

504th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

Is GlaxoSmithKline a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GlaxoSmithKline stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View analyst ratings for GlaxoSmithKline
or view top-rated stocks.

How has GlaxoSmithKline's stock been impacted by Coronavirus (COVID-19)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have increased by 3.5% and is now trading at $41.25.
View which stocks have been most impacted by COVID-19
.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 12,330,000 shares, a decrease of 20.9% from the October 31st total of 15,580,000 shares. Based on an average trading volume of 4,130,000 shares, the short-interest ratio is currently 3.0 days. Currently, 0.5% of the shares of the stock are short sold.
View GlaxoSmithKline's Short Interest
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, October, 27th. The pharmaceutical company reported $1.01 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.80 by $0.21. The pharmaceutical company earned $12.51 billion during the quarter, compared to analysts' expectations of $11.92 billion. GlaxoSmithKline had a trailing twelve-month return on equity of 26.27% and a net margin of 13.01%.
View GlaxoSmithKline's earnings history
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Friday, October 29th. Stockholders of record on Friday, November 19th will be given a dividend of $0.5234 per share on Thursday, January 13th. This represents a $2.09 annualized dividend and a dividend yield of 5.08%. The ex-dividend date is Thursday, November 18th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.52.
View GlaxoSmithKline's dividend history
.

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.06 per share and currently has a dividend yield of 4.98%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. GlaxoSmithKline does not yet have a strong track record of dividend growth. The dividend payout ratio of GlaxoSmithKline is 87.29%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 63.19% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.
View GlaxoSmithKline's dividend history.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of $1.560-$1.590 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.860. The company issued revenue guidance of -.

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Emma N. Walmsley, Chief Executive Officer & Executive Director
  • Iain James Mackay, Chief Financial Officer & Executive Director
  • Jon Ellis, VP & Head-Technology Business Development
  • Karenann K. Terrell, Chief Digital & Technology Officer
  • Hal V. Barron, Executive Director & Chief Scientific Officer

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.66%), Black Creek Investment Management Inc. (0.38%), Renaissance Technologies LLC (0.35%), Hotchkis & Wiley Capital Management LLC (0.34%), JTC Employer Solutions Trustee Ltd (0.23%) and BNP Paribas Arbitrage SA (0.22%).
View institutional ownership trends for GlaxoSmithKline
.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including JTC Employer Solutions Trustee Ltd, Boston Common Asset Management LLC, SG Americas Securities LLC, Hotchkis & Wiley Capital Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Macquarie Group Ltd., Jane Street Group LLC, and John G Ullman & Associates Inc..
View insider buying and selling activity for GlaxoSmithKline
or view top insider-selling stocks.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Black Creek Investment Management Inc., The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Bank of New York Mellon Corp, and Fisher Asset Management LLC.
View insider buying and selling activity for GlaxoSmithKline
or or view top insider-buying stocks.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $41.25.

How much money does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $111.07 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.36 on an earnings per share basis.

How many employees does GlaxoSmithKline have?

GlaxoSmithKline employs 94,066 workers across the globe.

When was GlaxoSmithKline founded?

GlaxoSmithKline was founded in 2000.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

Where are GlaxoSmithKline's headquarters?

GlaxoSmithKline is headquartered at 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 442080475000, via email at [email protected], or via fax at 44-20-8047-7807.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.